Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
SMS Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 2/4
SMS Pharmaceuticals' CEO is Ramesh Potluri, appointed in Aug 1990, has a tenure of 34.17 years. total yearly compensation is ₹36.88M, comprised of 81.4% salary and 18.6% bonuses, including company stock and options. directly owns 36.22% of the company’s shares, worth ₹11.48B. The average tenure of the management team and the board of directors is 5.4 years and 2.3 years respectively.
Anahtar bilgiler
Ramesh Potluri
İcra Kurulu Başkanı
₹36.9m
Toplam tazminat
| CEO maaş yüzdesi | 81.4% |
| CEO görev süresi | 34.2yrs |
| CEO sahipliği | 36.2% |
| Yönetim ortalama görev süresi | 5.4yrs |
| Yönetim Kurulu ortalama görev süresi | 2.3yrs |
Son yönetim güncellemeleri
SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24
Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23Recent updates
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Meaningful Debt Burden
Dec 09Should You Take Comfort From Insider Transactions At SMS Pharmaceuticals Limited (NSE:SMSPHARMA)?
Nov 18CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹570m |
| Mar 31 2024 | ₹37m | ₹30m | ₹498m |
| Dec 31 2023 | n/a | n/a | ₹361m |
| Sep 30 2023 | n/a | n/a | ₹288m |
| Jun 30 2023 | n/a | n/a | ₹150m |
| Mar 31 2023 | ₹31m | ₹30m | -₹71m |
| Dec 31 2022 | n/a | n/a | -₹42m |
| Sep 30 2022 | n/a | n/a | ₹9m |
| Jun 30 2022 | n/a | n/a | ₹259m |
| Mar 31 2022 | ₹38m | ₹26m | ₹622m |
| Dec 31 2021 | n/a | n/a | ₹789m |
| Sep 30 2021 | n/a | n/a | ₹911m |
| Jun 30 2021 | n/a | n/a | ₹791m |
| Mar 31 2021 | ₹47m | ₹21m | ₹625m |
| Dec 31 2020 | n/a | n/a | ₹458m |
| Sep 30 2020 | n/a | n/a | ₹319m |
| Jun 30 2020 | n/a | n/a | ₹308m |
| Mar 31 2020 | ₹26m | ₹20m | ₹316m |
| Dec 31 2019 | n/a | n/a | ₹386m |
| Sep 30 2019 | n/a | n/a | ₹405m |
| Jun 30 2019 | n/a | n/a | ₹406m |
| Mar 31 2019 | ₹32m | ₹20m | ₹400m |
| Mar 31 2018 | ₹32m | ₹20m | ₹317m |
Tazminat ve Piyasa: Ramesh 'nın toplam tazminatı ($USD 368.51K ) Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ( $USD 186.19K ).
Tazminat ve Kazançlar: Ramesh 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Ramesh Potluri (66 yo)
34.2yrs
Görev süresi
₹36,875,000
Tazminat
Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman & MD | 34.2yrs | ₹36.88m | 36.22% ₹ 11.5b | |
| Chief Financial Officer | 7.1yrs | ₹2.37m | Veri yok | |
| Company Secretary & Compliance Officer | 2.7yrs | ₹1.53m | Veri yok | |
| Executive Director | 3.8yrs | ₹36.83m | 15.74% ₹ 5.0b | |
| Assistant General Manager of HR and Legal | no data | Veri yok | Veri yok | |
| Head of HRD and General Manager of Purchases | no data | Veri yok | Veri yok |
5.4yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim: SMSPHARMA's management team is seasoned and experienced (5.4 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman & MD | 34.2yrs | ₹36.88m | 36.22% ₹ 11.5b | |
| Executive Director | 4.3yrs | ₹36.83m | 15.74% ₹ 5.0b | |
| Additional Non-Executive Non-Independent Director | less than a year | Veri yok | 2.58% ₹ 818.9m | |
| Non-Executive & Independent Director | 5.2yrs | ₹245.00k | Veri yok | |
| Non-Executive & Independent Director | 6.4yrs | ₹590.00k | 0.035% ₹ 11.2m | |
| Additional Non-Executive Independent Director | less than a year | Veri yok | Veri yok | |
| Non-Executive Non-Independent Director | less than a year | Veri yok | Veri yok | |
| Non-Executive Independent Director | less than a year | Veri yok | Veri yok |
2.3yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SMSPHARMA's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.